Abstract:Objective: Multiple myeloma (MM) is an incurable haematological cancer characterized by abnormal proliferation of plasma cells. The promising therapeutic effect of selective inhibitors of nuclear export in MM reveals the broad therapeutic prospects of nuclear localization intervention. Sterol regulatory element binding protein 2 (SREBP2) is a lipid regulatory molecule that has been implicated in the effect of drug therapy for MM. SREBP2 has been reported to be regulated by the antimalarial drug artesunate (ART) through alteration of its nuclear localization and has been shown to inhibit ferroptosis in other tumours. However, the mechanism through which this might occur has not been clarified in MM. Our study aimed to explore whether ART can induce ferroptosis in MM through nuclear localization of SREBP2. Methods: To evaluate whether ferroptosis is induced by treatment with ART in myeloma, we used two types of myeloma cell lines. We first used a series of molecular approaches and other techniques to investigate the impact of ART on cell growth, production of reactive oxygen species (ROS), Fe2+ levels, lipid peroxidation and expression of genes related to ferroptosis. Then, we further explored the mechanism through which ferroptosis may occur in these cells and the relationship between ferroptosis and the nuclear localization of SREBP2. Results: Upregulation of ROS, Fe2+, and lipid peroxidation as well as inhibition of cell growth were observed in myeloma cells after treatment with ART. Expression of acyl CoA synthase long chain family member 4 (ACSL4) was increased, while glutathione peroxidase 4 (GPX4) expression was reduced in cells treated with ART. ART-induced cell death could be reversed by ferropstatin-1 (Fer-1) and deferoxamine mesylate (DFO). Nuclear localization of SREBP2 in myeloma cells was inhibited, accompanied by downregulation of isopentenyl pyrophosphate (IPP) and GPX4, after treatment with ART. Conclusion: In conclusion, our study demonstrated that the antimalarial drug ART can inhibit nuclear localization of SREBP2, downregulate IPP and GPX4, and eventually trigger ferroptosis in myeloma cells. Through this study, we hope to establish a correlation between nuclear localization pathways and mediation of ferroptosis in myeloma cells and provide an innovative direction for exploration-related therapy.

Artesunate Induces Ferroptosis by Regulating MT1G and Has an Additive Effect with Doxorubicin in Diffuse Large B-cell Lymphoma Cells

Artesunate induces apoptosis, autophagy and ferroptosis in diffuse large B cell lymphoma cells by impairing STAT3 signaling

Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt's Lymphoma

Artesunate induces ferroptosis by inhibiting the nuclear localization of SREBP2 in myeloma cells

Enhanced lysosomal function is critical for paclitaxel resistance in cancer cells: reversed by artesunate

A Platinum(iv)-Artesunate Complex Triggers Ferroptosis by Boosting Cytoplasmic and Mitochondrial Lipid Peroxidation to Enhance Tumor Immunotherapy

Artesunate, a new antimalarial clinical drug, exhibits potent anti‐AML activity by targeting the ROS/Bim and TFRC/Fe<sup>2+</sup> pathways

Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways

Dihydroartemisinin Triggers Ferroptosis in Multidrug-Resistant Leukemia Cells

Artemisinin Derivatives Inhibit Non-small Cell Lung Cancer Cells Through Induction of ROS-dependent Apoptosis/Ferroptosis

Ferroptosis: A Novel Mechanism of Artemisinin and Its Derivatives in Cancer Therapy

Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma

Artesunate induces melanoma cell ferroptosis and augments antitumor immunity through targeting Ido1

Dependence of Artesunate on Long Noncoding RNA‐RP11 to Inhibit Epithelial‐mesenchymal Transition of Hepatocellular Carcinoma

Susceptibility of cervical cancer to dihydroartemisinin-induced ferritinophagy-dependent ferroptosis

Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation

Artesunate-loaded solid lipid nanoparticles resist esophageal squamous cell carcinoma by inducing Ferroptosis through inhibiting the AKT/mTOR signaling

Artesunate Synergistically Promotes Sorafenib‑induced Apoptosis and Ferroptosis in Non‑hodgkin Lymphoma Cells Through Inhibition of the STAT3 Pathway.

Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide.

The Effects Of Artesunate On The Expression Of Egfr And Abcg2 In A549 Human Lung Cancer Cells And A Xenograft Model

Artesunate Enhances Adriamycin Cytotoxicity by Inhibiting Glycolysis in Adriamycin-Resistant Chronic Myeloid Leukemia K562/ADR Cells.